This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Sweta Killa
Sector ETF report for PSCH
Blueprint Medicines (BPMC) Q2 Loss Widens, Sales Top Mark
by Zacks Equity Research
Blueprint Medicines (BPMC) suffers wider-than-expected loss in the second quarter while sales beat estimates.
Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Acorda (ACOR) posts narrower-than-expected loss while revenues top estimates in the second quarter. Inbrija delivers a solid start with sales rising sequentially.
Agios' (AGIO) Loss Widens in Q2, Tibsovo Drives Sales
by Zacks Equity Research
Agios (AGIO) incurs wider-than-expected loss in Q2 while revenues beat estimates. The company's newly approved leukemia drug Tibsovo sees a rise in sales sequentially.
Vertex (VRTX) Beats on Q2 Earnings, Ups CF Product Sales View
by Zacks Equity Research
Vertex (VRTX) beats on earnings and sales in second-quarter 2019. The company lifts its full-year revenue guidance, led by a solid CF products' performance, especially Symdeko.
Repligen (RGEN) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of 24.00% and 10.10%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Powell Gives Space for Growth, Market Overreacts: 5 Picks
by Nalak Das
Although market participants were expecting a quarter percentage point of cut, they were taken aback by Fed Chair Jerome Powell's comment that this rate cut is "in the nature of a mid-cycle adjustment to policy."
The Zacks Analyst Blog Highlights: Repligen, Tandem Diabetes Care, Telephone and Data Systems, Sunoco and Rent-A-Center
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Repligen, Tandem Diabetes Care, Telephone and Data Systems, Sunoco and Rent-A-Center
5 Top Picks on Three Key Takeaways From Q2 U.S. GDP
by Nalak Das
A closer look at the second-quarter GDP will help us to make three important inferences, which are expected to give guidance on the economy and stock market in the near term.
Medicines Company (MDCO) Q2 Earnings Top, Inclisiran in View
by Zacks Equity Research
The Medicines Company (MDCO) posts narrower-than-expected loss in Q2. The company did not generate any revenues in the period while its focus is steady on its sole pipeline candidate, inclisiran.
Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Repligen (RGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat in Store for Repligen (RGEN) This Earnings Season?
by Zacks Equity Research
On Repligen's (RGEN) second-quarter earnings call, investor focus will be on its advancement with the proposed acquisition of C Technologies, Inc.
Is Repligen (RGEN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (RGEN) Outperforming Other Medical Stocks This Year?
NuCana Initiates Dosing in Phase I Study for Solid Tumors
by Zacks Equity Research
NuCana (NCNA) doses the first patient in a phase I study on NUC-7738, which is being evaluated for the treatment of advanced solid tumors.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Inovio Ends Enrollment in Vulvar Dysplasia Study on VGX-3100
by Zacks Equity Research
Inovio (INO) closes enrollment in the phase II study, evaluating VGX-3100 for the treatment of HPV-related vulvar dysplasia.
Here is Why Growth Investors Should Buy Repligen (RGEN) Now
by Zacks Equity Research
Repligen (RGEN) could produce exceptional returns because of its solid growth attributes.
The Zacks Analyst Blog Highlights: Core-Mark, Repligen, Aaron's, HubSpot and Quanex Building Products
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Core-Mark, Repligen, Aaron's, HubSpot and Quanex Building Products
U.S. Economy Likely to Sustain Longest Expansion: 5 Top Picks
by Nalak Das
Despite the presence of near-term concerns, a closer look at the U.S. economy has a different story to tell, with enough reasons for further expansions.
Puma Biotech Submits sNDA for Breast Cancer Drug Nerlynx
by Zacks Equity Research
Puma Biotech (PBYI) files an sNDA for the nod of Nerlynx in combination with Xeloda to treat patients with HER2-positive metastatic breast cancer, having failed two or more prior lines of treatments.
Inovio Up on Enrollment Closure in Cervical Dysplasia Study
by Zacks Equity Research
Inovio (INO) concludes enrollment in the phase III study (REVEAL 1), which currently evaluates VGX-3100 for the treatment of cervical dysplasia, caused by HPV. Shares rally.
Pacira Gets EMA Acceptance for Pain Management Drug Exparel
by Zacks Equity Research
The EMA authorizes Pacira's (PCRX) marketing application for Exparel (bupivacaine liposome injectable suspension) to treat postsurgical pain.
Nabriva Gets EMA Acceptance for Pneumonia Drug Lefamulin
by Zacks Equity Research
The EMA endorses Nabriva Therapeutics' (NBRV) marketing application for both the intravenous and oral formulations of lefamulin to treat adult patients with community-acquired pneumonia.
Repligen Corporation (RGEN) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Repligen Corporation (RGEN).